ThyTech® is a biotechnology company focused on the development of innovative cell therapies based on regulatory T cells for patients with serious immunological and inflammatory disorders
Spin-off of the Gregorio Marañón General University Hospital
Thytech® has developed thyTregs™, a cell therapy platform leveraging the therapeutic potential of regulatory T cells (Tregs) purified from their natural source, the pediatric thymus, a tissue that is typically discarded during certain pediatric cardiac surgeries.
This tissue represents a unique source of Tregs, a type of immune cell essential for maintaining immune balance and preventing excessive inflammatory or autoimmune responses.
These thyTregs™ are excellent candidates for the treatment and prevention of severe immune system imbalances underlying numerous acute and chronic conditions.
Beyond pediatric heart transplantation, ThyTech’s technology platform holds significant potential for application in other clinical indications, including various types of organ transplants, autoimmune diseases, severe inflammatory conditions, and chronic inflammatory disorders, in both pediatric and adult patients.
In this endeavor, the company benefits from the strategic support of Farmalider, a Spanish pharmaceutical-biotech company with over 40 years of experience in pharmaceutical development, industrial manufacturing, and international regulatory affairs.
Farmalider brings to ThyTech its expertise in business development, regulatory support, technical guidance, and industrial manufacturing capabilities under international quality standards, helping to consolidate the company and advance its evolution toward a scalable, reproducible model prepared for future development phases.
Subvencionado por el Programa NEOTEC del CDTI
(SNEO-20241137)
Proyecto CPP2024-011294 financiado por:
